Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Amber C Streifel"'
Autor:
Amber C. Streifel, Jose Eduardo Rivera Sarti, Monica K. Sikka, Michael Conte, Bradie Winders, Cara D. Varley
Publikováno v:
Therapeutic Advances in Infectious Disease, Vol 11 (2024)
Background: Rates of serious injection-related infections in persons who use drugs have increased. Resulting admissions are an opportunity for screening and vaccination of preventable infections such as hepatitis A virus (HAV), hepatitis B virus (HBV
Externí odkaz:
https://doaj.org/article/f5b080d6cc66454da9f914211b97b844
Autor:
Alyse H. Douglass, Heather Mayer, Kathleen Young, Monica K. Sikka, Luke Strnad, Jina Makadia, Ellie Sukerman, James S. Lewis, Amber C. Streifel
Publikováno v:
Therapeutic Advances in Infectious Disease, Vol 10 (2023)
Background: Serious infections in persons who use drugs (PWUD) are rising. Dalbavancin, due to its extended half-life, offers an alternative treatment for patients in whom standard of care antibiotics are not feasible or practical, allowing for reduc
Externí odkaz:
https://doaj.org/article/fce8e939a9294723a8bd4d7f7ce73273
Publikováno v:
BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-6 (2022)
Abstract Background Corynebacterium striatum is a gram-positive facultative anaerobe found in the environment and human flora that has historically been considered a contaminant. More recently, Corynebacterium striatum has been implicated in human in
Externí odkaz:
https://doaj.org/article/0143416815674e5893716b854479168e
Screening for co-infections in patients with substance use disorders and severe bacterial infections
Publikováno v:
Therapeutic Advances in Infectious Disease, Vol 9 (2022)
Background: Patients with substance use disorders admitted for severe bacterial infection are in a prime position to be screened for important co-infections. However, data suggest that standard screening for co-infections in this population during ho
Externí odkaz:
https://doaj.org/article/c9ea9cc1963b4adcbc0173ef5ea46583
Publikováno v:
Therapeutic Advances in Infectious Disease, Vol 9 (2022)
Background: Patients with substance use disorders (SUDs) and severe bacterial infections requiring prolonged antibiotic therapy represent a significant challenge to providers due to complexity of care coordination required to ensure safe and effectiv
Externí odkaz:
https://doaj.org/article/e281a14229114c669d1bc40a1b167cf2
Publikováno v:
Open Forum Infectious Diseases. 9
Background Patients with substance used disorder (SUD) are at high risk of hepatitis c virus (HCV) infection. During admission for acute illness, patients with SUD are often screened for or known to have untreated chronic HCV with outpatient follow-u
Autor:
Amber C Streifel, Luke Strnad, Ellie Sukerman, Jina T Makadia, James S Lewis, Alyse H Douglass, Kathleen Young, Heather Mayer, Monica K Sikka
Publikováno v:
Open Forum Infectious Diseases. 9
Background Dalbavancin (DAL) provides an alternative to daily intravenous (IV) antibiotics for the treatment of infections when treatment in the outpatient setting is not practical. While clinical outcomes data for the treatment of osteomyelitis (OM)
Autor:
Alyse H Douglass, Heather Mayer, Kathleen Young, Amber C Streifel, Heather Franklin, Luke Strnad, Jina T Makadia, Monica K Sikka
Publikováno v:
Open Forum Infectious Diseases. 9
Background Persons who use drugs (PWUD) admitted for serious infections face many challenges when long courses of intravenous (IV) antibiotics are recommended. OPTIONS-DC is a structured multidisciplinary care conference used to navigate some of thes
Publikováno v:
Open Forum Infectious Diseases. 9
Background Dalbavancin provides an alternative to standard of care intravenous (IV) antibiotics for the treatment of complicated infections, although clinical data continues to evolve In the United States, the use of dalbavancin as an alternative for
Autor:
Hita Bhagat, Monica K. Sikka, Ellie S. Sukerman, Jina Makadia, James S. Lewis, Amber C. Streifel
Publikováno v:
The Annals of pharmacotherapy. 57(2)
Background: The OVIVA trial suggests oral antibiotics are an alternative to intravenous antibiotics to treat bone and joint infections (BJI). A shift in practice to treatment with oral antibiotics would eliminate the need for central vascular access,